 |
14 Products |  |
223 Diseases | | 14 Products |
|
9 Trials |  |
2094 News |  |
| «12345678910111213...1617» |
- || imatinib (AER-901) / Aerami Therap
Trial completion date, Trial primary completion date: Safety, Tolerability, & Pharmacokinetics Study of Single & Multiple Inhaled Doses of Imatinib Inhalation Solution (clinicaltrials.gov) - Feb 16, 2022
P1, N=78, Recruiting, Sponsor: Aerami Therapeutics
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- || Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P2 trial: Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma (clinicaltrials.gov) - Feb 2, 2022
P2, N=36, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- || Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Trial completion date, Trial primary completion date, Adherence: ADITION: Digital Adherence Monitoring of Inhalative Therapy in Real- Life Conditions (clinicaltrials.gov) - Jan 31, 2022
P=N/A, N=1000, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: Jun 2022 --> Dec 2022
- | Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Journal: Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma. (Pubmed Central) - Jan 29, 2022
The recently approved single-inhaler indacaterol/glycopyrronium/mometasone fixed dose combination has demonstrated to significantly reduce exacerbations, improve FEV, symptoms and quality of life compared to ICS/LABA, including, salmeterol/fluticasone combination. Moreover, once-daily dosing may improve adherence.
- || fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Clinical, Journal, Combination therapy: Clinical Interpretation of Efficacy Outcomes in Pharmacological Studies on Triple Fixed-Dose Combination Therapy for Uncontrolled Asthma: Assessment of IRIDIUM and ARGON Studies. (Pubmed Central) - Jan 21, 2022
Overall, HD-MF/IND/GLY induced greater clinically relevant benefits even when compared to HD-FLU/SAL + TIO. Considering that a balanced triple MF/IND/GLY FDC with MD ICS resulted as effective as HD-MF/IND in preventing moderate or severe exacerbations, thus triple ICS/LABA/LAMA FDCs with MD ICS should be considered for the treatment not only of uncontrolled asthma but also for those patients suffering from less severe forms of disease with airflow limitation as well as a possible as-needed therapeutic option.
- ||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
P3 data, Retrospective data, Journal: Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials. (Pubmed Central) - Dec 18, 2021
There was no evidence of increased cardiovascular risk attributable to the addition of IND to MF or addition of GLY to MF/IND. Similarly, no evidence of increased cardiovascular risk was observed with an increase in the ICS-dose or relative to F/S ± TIO.
- || Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Clinical, PK/PD data, Journal, Combination therapy: Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler Device in Patients with Asthma. (Pubmed Central) - Dec 18, 2021
The pharmacokinetic profiles of MF were comparable for combination products at corresponding medium- or high-dose inhaled corticosteroids. On a population level, the pharmacokinetics of IND and GLY were comparable between patients with asthma and COPD.
- || Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: XPERTT: Investigating the Effects of QVM149 on MRI Ventilation Defects (clinicaltrials.gov) - Dec 14, 2021
P3, N=0, Withdrawn, Sponsor: Dr. Grace Parraga
On a population level, the pharmacokinetics of IND and GLY were comparable between patients with asthma and COPD. N=48 --> 0 | Trial completion date: Jul 2021 --> Dec 2022 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2021 --> Jul 2022
- || Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Clinical, Journal, HEOR: Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada. (Pubmed Central) - Dec 13, 2021
IND/GLY/MF was the most cost-effective option in all scenarios tested. IND/GLY/MF was cost-effective at a willingness-to-pay threshold of CAD $50,000/QALY in patients with uncontrolled, moderate-to-severe asthma versus SAL/FLU+TIO and SAL/FLU in the base case and all scenarios tested.
- || Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Trial initiation date: SENSE: An Observational Prospective Study to Characterize Patients Initiating Enerzair® Breezhaler®, With or Without Sensor, as a Maintenance Treatment for Asthma (clinicaltrials.gov) - Dec 10, 2021
P=N/A, N=160, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
IND/GLY/MF was cost-effective at a willingness-to-pay threshold of CAD $50,000/QALY in patients with uncontrolled, moderate-to-severe asthma versus SAL/FLU+TIO and SAL/FLU in the base case and all scenarios tested. Initiation date: Nov 2021 --> Feb 2022
- || Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Clinical, Retrospective data, Journal: Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population. (Pubmed Central) - Nov 29, 2021
One time per day, single-inhaler IND/GLY/MF improved lung function, reduced asthma exacerbations and provided comparable asthma control versus IND/MF and SAL/FLU in Asian patients with inadequately controlled asthma despite LABA/ICS. The results of this analysis were consistent with the overall population in the IRIDIUM study.
- |||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
New trial: SENSE: An Observational Prospective Study to Characterize Patients Initiating Enerzair® Breezhaler®, With or Without Sensor, as a Maintenance Treatment for Asthma (clinicaltrials.gov) - Nov 16, 2021
P=N/A, N=160, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Comparative Efficacy and Safety Between Budesonide-formoterol and Fluticasone-salmeterol Combination Inhalers for Asthma Management: Retrospective Analysis from the Common Data Model (Pearl) - Nov 15, 2021 - Abstract #KATRDIC2021KATRDIC_230;
- fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
[VIRTUAL] Emergency room visits and rescue medication use in patients with asthma in the IRIDIUM study and their impact on carbon footprint () - Nov 10, 2021 - Abstract #BTSWMI2021BTS_WM_I_168;
Nonetheless, these results might be used as a basis for conducting studies on carbon footprint in patients with asthma. The study was funded by Novartis Pharmaceuticals, East Hanover.
- || Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
Clinical, Review, Journal: Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ indacaterol/glycopyrronium in patients with asthma. (Pubmed Central) - Nov 6, 2021
Following this stepwise approach, it was determined that mometasone furoate 80 μg o.d. (medium dose strength) and 160 μg o.d. (high dose strength) in mometasone furoate/indacaterol acetate/glycopyrronium bromide formulation provided comparable inhaled corticosteroid efficacy to mometasone furoate 160 μg o.d. (medium dose strength) and 320 μg o.d. (high dose strength) in the mometasone furoate/indacaterol acetate formulation, respectively. These doses were used in the PLATINUM Phase III clinical program that investigated the efficacy and safety of mometasone furoate/indacaterol acetate and mometasone furoate/indacaterol acetate/glycopyrronium bromide combinations in patients with asthma.
- || Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Review, Journal: Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma. (Pubmed Central) - Nov 4, 2021
Indacaterol/glycopyrronium/mometasone was generally well tolerated, and the most common adverse events were respiratory in nature. In conclusion, combination therapy with indacaterol/glycopyrronium/mometasone represents a valuable option for the maintenance treatment of asthma, with the convenience of once-daily administration via a single inhaler.
- | Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis, Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
Journal: Fixed combination of mometasone, indacaterol, glycopyrronium for the treatment of severe asthma : Enerzair® Breezhaler® (Pubmed Central) - Oct 12, 2021
As compared to an ICS/LABA combination Enerzair® improves expiratory flow rates and reduces exacerbation rate. The Breezhaler® device may be coupled to a sensor (Propeller Health) that, through a bluetooth system, allows to control patient adherence and provides recall to the patient to take his aerosol.
- || Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Clinical, PK/PD data, Journal: Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects. (Pubmed Central) - Sep 19, 2021
Multiple inhaled doses of IND, GLY and MF were safe and well tolerated, when administered alone or in combination. There was no clinically relevant pharmacokinetic interaction between IND, GLY and MF when administered as IND/GLY/MF.
- ||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Nuevos datos de Novartis sobre Enerzair Breezhaler en #asma no controlado @Novartis #ERS2021 - https://t.co/3O8hPgMjA1 (Twitter) - Sep 8, 2021
- || Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Clinical, PK/PD data, Journal: Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects. (Pubmed Central) - Sep 8, 2021
Pharmacokinetics of IND, GLY and MF (high and medium dose) when delivered as a fixed-dose combination were comparable between Japanese and Caucasian subjects. The IND/GLY/MF combination at the administrated doses was safe and well tolerated in both ethnic groups.
- || Onbrez (indacaterol) / Novartis
Clinical, Journal, HEOR: Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Agonist and a High Dose of an Inhaled Corticosteroid Who Experienced One or More Asthma Exacerbations in the Previous Year. (Pubmed Central) - Sep 2, 2021
The IND/GLY/MF combination at the administrated doses was safe and well tolerated in both ethnic groups. The results indicate that IND/GLY/MF is cost effective against the considered comparators in a cohort representative of adult patients with asthma in Italy.
- | KN-002 / Vectura, Kinaset Therap
New P1 trial: Single and Multiple Ascending Dose Study of KN-002 (clinicaltrials.gov) - Aug 16, 2021
P1, N=80, Recruiting, Sponsor: Kinaset Therapeutics Inc
- Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
[VIRTUAL] Assessment of patient engagement and adherence with once-daily indacaterol/glycopyrronium/mometasone (IND/GLY/MF) Breezhaler digital companion in asthma: interim analysis from Germany (Channel 2) - Jul 29, 2021 - Abstract #ERS2021ERS_4500;
At 3-month follow-up (n=42), mean daily adherence was 82% (Table) Conclusions Patients using Breezhaler® digital companion showed good medication adherence (82%) and app engagement. Long-term data from this program may help understand factors associated with improved medication adherence and app engagement in these patients
- Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
[VIRTUAL] Mometasone/indacaterol/glycopyrronium (MF/IND/GLY) improves lung function and reduces exacerbations in patients with asthma, independent of baseline airflow limitation: Results from IRIDIUM study () - Jul 29, 2021 - Abstract #ERS2021ERS_4436;
P3
Results In all subgroups, high-dose MF/IND/GLY showed greater improvement in trough FEV1 and reduction in annualised rate of exacerbations vs high-dose FLU/SAL, and greater improvement in trough FEV1 vs high-dose MF/IND, which was in line with overall population (Table). A proportion of pts did not normalise their lung function even after maximal bronchodilation and prolonged steroids, suggesting an element of fixed airway obstruction Conclusion Improvements in lung function and exacerbations with high-dose MF/IND/GLY vs high-dose MF/IND and FLU/SAL were independent of severity of airflow limitation at baseline
- Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
[VIRTUAL] Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study () - Jul 29, 2021 - Abstract #ERS2021ERS_4435;
P3
Conclusion In pts with inadequately controlled asthma with high-dose ICS/LABA, comparable FEV1 improvement and a trend toward exacerbation rate reduction were seen with high-dose than medium-dose MF/IND/GLY. These results suggest high-dose MF/IND/GLY as step-up therapy provides better clinical benefit than medium-dose MF/IND/GLY.
- Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
[VIRTUAL] Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study () - Jul 29, 2021 - Abstract #ERS2021ERS_4434;
P3
Conclusion In pts with inadequately controlled asthma with medium-dose ICS/LABA, greater lung function improvement and exacerbation reduction were observed with both doses of MF/IND/GLY vs high-dose FLU/SAL. These results suggest use of MF/IND/GLY as step-up therapy from medium-dose ICS/LABA provides benefit beyond increasing ICS dose.
- Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
[VIRTUAL] Mometasone/ indacaterol/ glycopyrronium demonstrates similar efficacy in men and women: post hoc analysis of IRIDIUM study () - Jul 29, 2021 - Abstract #ERS2021ERS_4433;
P3
As for ACQ-7 scores, rescue medication use, rate of exacerbations and safety, treatment effects were consistent across genders with MF/IND/GLY vs FLU/SAL. Conclusions Medium- or high-dose MF/IND/GLY o.d. improved lung function vs high-dose FLU/SAL b.i.d., independent of gender.
- Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
[VIRTUAL] Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus fluticasone/salmeterol (FLU/SAL) in ex-smoker and never smoker patients with inadequately controlled asthma: Post hoc analysis of IRIDIUM study () - Jul 29, 2021 - Abstract #ERS2021ERS_4431;
P3
There were trends for greater reduction in exacerbations with both doses of MF/IND/GLY vs high-dose FLU/SAL, with no clear difference dependent on smoking pattern (Figure 1B). Conclusion Both doses of MF/IND/GLY showed benefit in lung function and asthma exacerbations vs high-dose FLU/SAL independent of smoking history, indicating no effect of smoking history on efficacy of MF/IND/GLY.
- Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
[VIRTUAL] Mometasone/indacaterol (MF/IND) and mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus fluticasone/salmeterol (FLU/SAL) and FLU/SAL+tiotropium (TIO) in patients with inadequately controlled asthma: data from the PLATINUM program () - Jul 29, 2021 - Abstract #ERS2021ERS_4429;
Improvements in trough FEV1 and ACQ-7 were maintained until Wk 52. All treatments were well tolerated Conclusion MF/IND and MF/IND/GLY demonstrated clinical benefit vs widely used asthma treatments and represent novel o.d. treatment options for patients with inadequately controlled asthma
- Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD), Onbrez (indacaterol) / Novartis
[VIRTUAL] Evaluating contributions of mometasone (MF), indacaterol (IND) and glycopyrronium (GLY) to reduction of exacerbations in patients with inadequately controlled asthma: Results from the IRIDIUM study (Channel 2) - Jul 29, 2021 - Abstract #ERS2021ERS_2442;
P3
Pooled MF/IND/GLY showed reduction in moderate/severe (14%), severe (15%) and all exacerbations (17%) vs pooled MF/IND, highlighting potential role of GLY in exacerbation reduction. High-dose MF/IND showed reductions in moderate/severe (25%), severe (27%) and all exacerbations (25%) vs high-dose FLU/SAL, showing benefits of MF and IND Conclusion Data analysis evaluated in context of 36-42% reduction observed with high-dose MF/IND/GLY vs FLU/SAL in IRIDIUM study highlight considerable contributions of GLY, IND and MF to exacerbation reduction
- Onbrez (indacaterol) / Novartis
[VIRTUAL] Indacaterol acetate, glycopyrronium bromide, and mometasone furoate: effect on neuronal inflammation and acetylcholine release () - Jul 29, 2021 - Abstract #ERS2021ERS_2089;
Results are shown in Figure 1 A-D.Conclusions IND/MF and IND/GLY/MF combinations modulated neuronal inflammation in a synergistic manner, but only IND/GLY/MF combination reduced the release of non-neuronal ACh. These observations may explain the efficacy of IND/MF and IND/GLY/MF observed in clinical studies.
- KN-002 / Vectura, Kinaset Therap
[VIRTUAL] The pan janus kinase (JAK) inhibitor KN-002 suppresses inflammatory mediator release from severe asthma bronchial epithelial cells. () - Jul 29, 2021 - Abstract #ERS2021ERS_2087;
KN-002 is a potent and broad inhibitor of IL-13- and IFNγ+TNFα-induced inflammation implicated in the pathogenesis of Th2-high and Th2-low asthma ex vivo. The data support a potential therapeutic role in severe asthma and COPD.
- Onbrez (indacaterol) / Novartis
[VIRTUAL] Indacaterol acetate, glycopyrronium bromide, and mometasone furoate: effect on human airway inflammation () - Jul 29, 2021 - Abstract #ERS2021ERS_2084;
Conclusions The synergy elicited by IND/MF and IND/GLY/MF combinations prevented the release of cytokines, with the concentrations of MF modulating the anti-inflammatory effects in passively sensitized bronchi. These data may explain the efficacy of IND/MF and IND/GLY/MF observed in clinical studies.
- | Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Journal, Heterogeneity: Ventilation heterogeneity and oscillometry predict asthma control improvement following step-up inhaled therapy in uncontrolled asthma. (Pubmed Central) - Jun 26, 2021
Step-up to high-dose combination treatment in uncontrolled asthma is associated with improved peripheral airway function as measured by Xrs and MBNW. Baseline MBNW and FOT parameters correlated with the improvement in symptoms and may predict a positive response to up-titration in uncontrolled asthmatic patients.
- ||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Clinical, P3 data, Journal, Head-to-Head: Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON). (Pubmed Central) - Jun 8, 2021
IND/GLY/MF high- and medium-dose o.d. via a single inhaler were non-inferior to SAL/FLU high-dose b.i.d. + TIO o.d. via two inhalers for AQLQ. IND/GLY/MF high-dose o.d. improved lung function, asthma control and health status versus SAL/FLU high dose + TIO, while IND/GLY/MF medium-dose had comparable efficacy but at a corresponding lower steroid dose.
- ||| fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Clinical, Review, Journal, Adverse events, Serious adverse event: Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. (Pubmed Central) - Jun 1, 2021
Only 46 non-fatal serious adverse events were thought to be asthma related; this small number in addition to the absence of independent outcome assessment means that we have very low confidence for this outcome. We found no evidence of safety issues that would affect the choice between salmeterol and formoterol combination inhalers used for regular maintenance therapy by adults and children with asthma.
- || Onbrez (indacaterol) / Novartis
Clinical, Journal: Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients. (Pubmed Central) - May 27, 2021
Mean values and distributions of the deposited lung doses proved to be both drug and device specific, yielding 24.2 (±7.8), 22.6 (±3.6), 34.2 (±4.8) and 23.9 (±5.4) % values for Symbicort®, Onbrez®, Seebri® and Bretaris®, respectively...A more powerful inhalation significantly increases the lung dose for the drug emitted by Turbuhaler®, while long breath-hold is likely to yield significantly higher deposition for drugs emitted by Breezhaler® and Genuair®. Lung doses of two different drugs dispensed in the same inhaler can be significantly different.
- | imatinib (AER-901) / Aerami Therap
New P1 trial: Safety, Tolerability, & Pharmacokinetics Study of Single & Multiple Inhaled Doses of Imatinib Inhalation Solution (clinicaltrials.gov) - May 25, 2021
P1, N=78, Recruiting, Sponsor: Aerami Therapeutics
- || fluticasone / Generic mfg., fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Retrospective data, Review, Journal: The efficacy and safety of fluticasone propionate/formoterol compared with fluticasone propionate/salmeterol in treating pediatric asthma: a systematic review and meta-analysis. (Pubmed Central) - May 15, 2021
Compared with FP/FORM, FP/SAL showed a clear improvement in pre-dose FEV, asthma symptom scores, and sleep disturbance scores. However, FP/FORM resulted in improved PEFR with a lower incidence of nasopharyngitis.
- || Triglide (fenofibrate) / Vectura, Shionogi
Clinical, Journal: Efficacy and safety of Coenzyme A versus fenofibrate in patients with hyperlipidemia: a multicenter, double-blind, double-mimic, randomized clinical trial. (Pubmed Central) - Apr 30, 2021
Compared with fenofibrate, CoA has less effect on reducing plasma TG levels in subjects with moderate dyslipidemia. However, it has fewer adverse effects.
- || Triglide (fenofibrate) / Vectura, Shionogi
Clinical, Journal: The Efficacy of Intravenous Insulin Infusion in the Management of Hypertriglyceridemia-Induced Pancreatitis in a Rural Community Hospital. (Pubmed Central) - Apr 30, 2021
Her triglyceride levels decreased rather quickly to 4783 mg/dL within 24 hours and by the fourth day of admission were comfortably <1000 mg/dL with insulin infusion along with clinical improvement. She was discharged on niacin and insulin therapy along with her home medications of statin and fenofibrate.
- | Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis, Proair digihaler (albuterol sulfate) / Teva
Journal: Dry powder inhalers: a concise summary of the electronic monitoring devices. (Pubmed Central) - Apr 30, 2021
She was discharged on niacin and insulin therapy along with her home medications of statin and fenofibrate. No abstract available
- | Triglide (fenofibrate) / Vectura, Shionogi
Preclinical, Journal: NPC1L1 and ABCG5/8 induction explain synergistic fecal cholesterol excretion in ob/ob mice co-treated with PPAR-α and LXR agonists. (Pubmed Central) - Apr 29, 2021
Synergistic efficacy on fecal cholesterol excretion following co-treatment with PPAR-α and LXR agonists occurred through a combination of RCT, TICE, and the key enzyme in bile synthesis, cholesterol 7-α hydroxylase (cyp7a1). These results suggest that cholesterol efflux, biliary cholesterol excretion, and TICE collectively contributed to the 12-fold increases in the fecal cholesterol excretion in ob/ob mice co-treated with PPAR-α and LXR agonists.
- || Triglide (fenofibrate) / Vectura, Shionogi
Clinical, Retrospective data, Journal: Association Analysis of Hyperlipidemia with the 28-Day All-Cause Mortality of COVID-19 in Hospitalized Patients. (Pubmed Central) - Apr 27, 2021
Similar results were also obtained in subgroup analyses of abnormal lipid parameters. Therefore, hyperlipidemia might be not a major causative factor for poor outcome of COVID-19, which provides guidance for the intervention of inpatients during the epidemic of COVID-19.
- || Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Clinical, Journal: Lung function improvements following inhaled indacaterol/glycopyrronium/mometasone furoate are independent of dosing time in asthma patients: a randomised trial. (Pubmed Central) - Apr 27, 2021
IND/GLY/MF demonstrated a safety profile comparable with placebo. Once-daily inhaled IND/GLY/MF was well tolerated and provided sustained lung function improvements over 24 h, irrespective of a.m. or p.m. dosing, in patients with mild-moderate asthma.
- || Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Clinical, Journal: Lung Function Normalisation with Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Asthma. (Pubmed Central) - Apr 18, 2021
Once-daily inhaled IND/GLY/MF was well tolerated and provided sustained lung function improvements over 24 h, irrespective of a.m. or p.m. dosing, in patients with mild-moderate asthma. No abstract available
- ||| Triglide (fenofibrate) / Vectura, Shionogi
Colchicine undoubtedly works- the evidence is clear. There is no pharma push for the prescribing... just like fenofibrate for diabetic complications... this is where we need guidelines to step up (Twitter) - Apr 17, 2021
- | Triglide (fenofibrate) / Vectura, Shionogi
Journal: Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery. (Pubmed Central) - Apr 17, 2021
This is a directly actionable finding owing to the highly disease-relevant model tested. This platform can be easily modified to test any number of metabolic stressors and potential pharmacological interventions for future treatment discovery in retinal diseases.
- || Triglide (fenofibrate) / Vectura, Shionogi
Clinical, Journal: Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020. (Pubmed Central) - Apr 13, 2021
CVD risk reduction with icosapent ethyl treatment was comparable between women and men (p for interaction, 0.33). Data from REDUCE-IT suggest women benefit similarly to men with respect to icosapent ethyl, a novel therapy for prevention of CVD.
- | Triglide (fenofibrate) / Vectura, Shionogi, Aplidin (plitidepsin) / PharmaMar, Roche
Journal: Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen. (Pubmed Central) - Apr 13, 2021
Antivirals prioritized herein identify novel compounds and their mode of action, while independently replicating the activity of a reduced proportion of drugs which are mostly approved for clinical use. Combinations of these drugs should be tested in animal models to inform the design of fast track clinical trials.